UY29617A1 - Compuestos químicos vii - Google Patents

Compuestos químicos vii

Info

Publication number
UY29617A1
UY29617A1 UY29617A UY29617A UY29617A1 UY 29617 A1 UY29617 A1 UY 29617A1 UY 29617 A UY29617 A UY 29617A UY 29617 A UY29617 A UY 29617A UY 29617 A1 UY29617 A1 UY 29617A1
Authority
UY
Uruguay
Prior art keywords
chemical compounds
compounds vii
solvates
salts
prodrugs
Prior art date
Application number
UY29617A
Other languages
English (en)
Inventor
Hunegnaw Fana
Karlsson Staffan
Starke Ingemar
Dahlstrom Mikael
Peter Nordberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29617A1 publication Critical patent/UY29617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de fórmula (I), derivados de azetidinona, o sales, solvatos, solvatos de dichas sales y profármacos farmacéuticamente aceptables de los mismos. Poseen actividad inhibitoria de la absorción del colesterol y útiles para el tratamiento de estados de enfermedad asociados con condiciones hiperlipidémicas.
UY29617A 2005-06-22 2006-06-21 Compuestos químicos vii UY29617A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501467 2005-06-22

Publications (1)

Publication Number Publication Date
UY29617A1 true UY29617A1 (es) 2007-01-31

Family

ID=37570732

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29617A UY29617A1 (es) 2005-06-22 2006-06-21 Compuestos químicos vii

Country Status (18)

Country Link
US (1) US20100152156A1 (es)
EP (1) EP1896408A1 (es)
JP (1) JP2008546771A (es)
KR (1) KR20080020686A (es)
CN (1) CN101243045A (es)
AR (1) AR057380A1 (es)
AU (1) AU2006259895A1 (es)
BR (1) BRPI0611617A2 (es)
CA (1) CA2609994A1 (es)
EC (1) ECSP088099A (es)
IL (1) IL187739A0 (es)
MX (1) MX2007016484A (es)
NO (1) NO20076195L (es)
RU (1) RU2007147344A (es)
TW (1) TW200716543A (es)
UY (1) UY29617A1 (es)
WO (1) WO2006137794A1 (es)
ZA (1) ZA200710605B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
HUE026367T2 (en) 2010-05-04 2016-06-28 Codexis Inc Biocatalysts of ezetimibe synthesis
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US10449133B1 (en) 2018-08-23 2019-10-22 L'oreal Cosmetic compositions comprising acetyl trifluoromethylphenyl valylglycine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
SI1427409T1 (sl) * 2001-09-21 2009-02-28 Schering Corp Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US6761509B2 (en) * 2002-07-26 2004-07-13 Jan Erik Jansson Concrete module for retaining wall and improved retaining wall
US6960047B2 (en) * 2002-08-02 2005-11-01 Innovative Technology Application, Inc. Protection barrier apparatus
MXPA05009503A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7002008B2 (en) * 2003-06-16 2006-02-21 Bomi Patel Framroze Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005061452A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
WO2005062824A2 (en) * 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
KR100725758B1 (ko) * 2004-03-30 2007-06-08 삼성광주전자 주식회사 전동 송풍기 및 이를 이용한 자동차용 전동 과급기
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
US7498431B2 (en) * 2005-12-01 2009-03-03 Bomi Patel Framroze Process for the preparation of chiral azetidinones
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
CA2663434A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
US20100125059A1 (en) * 2007-03-06 2010-05-20 Teijin Pharma Limited 1-biarylazetidinone derivative

Also Published As

Publication number Publication date
IL187739A0 (en) 2008-08-07
BRPI0611617A2 (pt) 2011-05-31
MX2007016484A (es) 2008-03-07
AR057380A1 (es) 2007-11-28
EP1896408A1 (en) 2008-03-12
KR20080020686A (ko) 2008-03-05
RU2007147344A (ru) 2009-07-27
JP2008546771A (ja) 2008-12-25
ECSP088099A (es) 2008-02-20
ZA200710605B (en) 2008-12-31
WO2006137794A1 (en) 2006-12-28
CN101243045A (zh) 2008-08-13
NO20076195L (no) 2008-02-27
CA2609994A1 (en) 2006-12-28
US20100152156A1 (en) 2010-06-17
TW200716543A (en) 2007-05-01
AU2006259895A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
UY29616A1 (es) Compuestos químicos iii
UY29617A1 (es) Compuestos químicos vii
UY29615A1 (es) Compuestos quimicos iv
PA8680701A1 (es) Derivados de oxindol
UY29614A1 (es) Compuestos químicos
ECSP066302A (es) Omega-carboxiaril-difenil-urea sustituida con flúor para el tratamiento y la prevención de enfermedades y afecciones
CR8831A (es) Compuestos y metodos para el tratamiento de dislipidemia
CR9667A (es) Derivados de benzamida y usos relacionados con los mismos
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
ECSP078051A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
UY29607A1 (es) Compuestos quimicos
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
UY30835A1 (es) 8-alquinilxantinas y derivados
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
NO20062357L (no) Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer
EA200602157A1 (ru) Новые производные тетрагидропиридотиофена
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
EA200801107A1 (ru) Пиразолы, пригодные для лечения воспалений
DK1879580T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolinderivater som lægemidler til behandling af infertilitet
NO20082411L (no) Heterocykliske amidforbindelser og anvendelse derav

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160912